BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37167967)

  • 1. Targeting stromal cell sialylation reverses T cell-mediated immunosuppression in the tumor microenvironment.
    Egan H; Treacy O; Lynch K; Leonard NA; O'Malley G; Reidy E; O'Neill A; Corry SM; De Veirman K; Vanderkerken K; Egan LJ; Ritter T; Hogan AM; Redmond K; Peng L; Che J; Gatlin W; Jayaraman P; Sheehan M; Canney A; Hynes SO; Kerr EM; Dunne PD; O'Dwyer ME; Ryan AE
    Cell Rep; 2023 May; 42(5):112475. PubMed ID: 37167967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer-derived sialylated IgG promotes tumor immune escape by binding to Siglecs on effector T cells.
    Wang Z; Geng Z; Shao W; Liu E; Zhang J; Tang J; Wang P; Sun X; Xiao L; Xu W; Zhang Y; Cui H; Zhang L; Yang X; Chang X; Qiu X
    Cell Mol Immunol; 2020 Nov; 17(11):1148-1162. PubMed ID: 31754235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Siglec Signaling in the Tumor Microenvironment.
    van Houtum EJH; Büll C; Cornelissen LAM; Adema GJ
    Front Immunol; 2021; 12():790317. PubMed ID: 34966391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells.
    Lustig M; Chan C; Jansen JHM; Bräutigam M; Kölling MA; Gehlert CL; Baumann N; Mester S; Foss S; Andersen JT; Bastian L; Sondermann P; Peipp M; Burger R; Leusen JHW; Valerius T
    Front Immunol; 2023; 14():1178817. PubMed ID: 37346044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint inhibitors as mediators for immunosuppression by cancer-associated fibroblasts: A comprehensive review.
    Eskandari-Malayeri F; Rezaei M
    Front Immunol; 2022; 13():996145. PubMed ID: 36275750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer-associated fibroblasts promote an immunosuppressive microenvironment through the induction and accumulation of protumoral macrophages.
    Takahashi H; Sakakura K; Kudo T; Toyoda M; Kaira K; Oyama T; Chikamatsu K
    Oncotarget; 2017 Jan; 8(5):8633-8647. PubMed ID: 28052009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stromal Cell PD-L1 Inhibits CD8
    O'Malley G; Treacy O; Lynch K; Naicker SD; Leonard NA; Lohan P; Dunne PD; Ritter T; Egan LJ; Ryan AE
    Cancer Immunol Res; 2018 Nov; 6(11):1426-1441. PubMed ID: 30228206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colonic epithelial cells express specific ligands for mucosal macrophage immunosuppressive receptors siglec-7 and -9.
    Miyazaki K; Sakuma K; Kawamura YI; Izawa M; Ohmori K; Mitsuki M; Yamaji T; Hashimoto Y; Suzuki A; Saito Y; Dohi T; Kannagi R
    J Immunol; 2012 May; 188(9):4690-700. PubMed ID: 22467657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Siglec-6 as a New Potential Immune Checkpoint for Bladder Cancer Patients.
    Benmerzoug S; Chevalier MF; Verardo M; Nguyen S; Cesson V; Schneider AK; Dartiguenave F; Rodrigues-Dias SC; Lucca I; Jichlinski P; Roth B; Nardelli-Haefliger D; Derré L
    Eur Urol Focus; 2022 May; 8(3):748-751. PubMed ID: 34147404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives.
    Mao X; Xu J; Wang W; Liang C; Hua J; Liu J; Zhang B; Meng Q; Yu X; Shi S
    Mol Cancer; 2021 Oct; 20(1):131. PubMed ID: 34635121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Siglec-9 Regulates an Effector Memory CD8
    Haas Q; Boligan KF; Jandus C; Schneider C; Simillion C; Stanczak MA; Haubitz M; Seyed Jafari SM; Zippelius A; Baerlocher GM; Läubli H; Hunger RE; Romero P; Simon HU; von Gunten S
    Cancer Immunol Res; 2019 May; 7(5):707-718. PubMed ID: 30988027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment.
    van de Wall S; Santegoets KCM; van Houtum EJH; Büll C; Adema GJ
    Trends Immunol; 2020 Apr; 41(4):274-285. PubMed ID: 32139317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesenchymal stromal cells (MSCs) and colorectal cancer: a troublesome twosome for the anti-tumour immune response?
    O'Malley G; Heijltjes M; Houston AM; Rani S; Ritter T; Egan LJ; Ryan AE
    Oncotarget; 2016 Sep; 7(37):60752-60774. PubMed ID: 27542276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting glycosylated antigens on cancer cells using siglec-7/9-based CAR T-cells.
    Meril S; Harush O; Reboh Y; Matikhina T; Barliya T; Cohen CJ
    Mol Carcinog; 2020 Jul; 59(7):713-723. PubMed ID: 32391973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole-cell tumor vaccines desialylated to uncover tumor antigenic Gal/GalNAc epitopes elicit anti-tumor immunity.
    Huang J; Li M; Mei B; Li J; Zhu Y; Guo Q; Huang J; Zhang G
    J Transl Med; 2022 Oct; 20(1):496. PubMed ID: 36316782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer-Associated Fibroblasts Promote Immunosuppression by Inducing ROS-Generating Monocytic MDSCs in Lung Squamous Cell Carcinoma.
    Xiang H; Ramil CP; Hai J; Zhang C; Wang H; Watkins AA; Afshar R; Georgiev P; Sze MA; Song XS; Curran PJ; Cheng M; Miller JR; Sun D; Loboda A; Jia Y; Moy LY; Chi A; Brandish PE
    Cancer Immunol Res; 2020 Apr; 8(4):436-450. PubMed ID: 32075803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Potential of Siglecs and Sialic Acids as Biomarkers and Therapeutic Targets in Tumor Immunotherapy.
    Feng H; Feng J; Han X; Ying Y; Lou W; Liu L; Zhang L
    Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sialylation pattern in lung epithelial cell line and Siglecs expression in monocytic THP-1 cells as cellular indicators of cigarette smoke - induced pathology in vitro.
    Wielgat P; Trofimiuk E; Czarnomysy R; Holownia A; Braszko JJ
    Exp Lung Res; 2018 Apr; 44(3):167-177. PubMed ID: 29781747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression profiling of immune inhibitory Siglecs and their ligands in patients with glioma.
    Santegoets KCM; Gielen PR; Büll C; Schulte BM; Kers-Rebel ED; Küsters B; Bossman SAJFH; Ter Laan M; Wesseling P; Adema GJ
    Cancer Immunol Immunother; 2019 Jun; 68(6):937-949. PubMed ID: 30953118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.